Harrow, Inc. (HROW)
38.54
+0.28
(+0.73%)
USD |
NASDAQ |
Sep 04, 16:00
38.53
-0.01
(-0.03%)
Pre-Market: 20:00
Harrow Research and Development Expense (Quarterly) : 8.072M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.072M |
| March 31, 2026 | 5.895M |
| December 31, 2025 | 3.273M |
| September 30, 2025 | 3.323M |
| June 30, 2025 | 2.868M |
| March 31, 2025 | 3.026M |
| December 31, 2024 | 4.755M |
| September 30, 2024 | 2.273M |
| June 30, 2024 | 3.053M |
| March 31, 2024 | 2.149M |
| December 31, 2023 | 3.336M |
| September 30, 2023 | 1.421M |
| June 30, 2023 | 1.161M |
| March 31, 2023 | 0.734M |
| December 31, 2022 | 0.703M |
| September 30, 2022 | 0.775M |
| June 30, 2022 | 0.914M |
| March 31, 2022 | 0.658M |
| December 31, 2021 | 4.043M |
| September 30, 2021 | 6.125M |
| June 30, 2021 | 0.425M |
| March 31, 2021 | 0.592M |
| December 31, 2020 | 0.591M |
| September 30, 2020 | 0.67M |
| June 30, 2020 | 0.749M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.403M |
| December 31, 2019 | 0.424M |
| September 30, 2019 | 0.444M |
| June 30, 2019 | 0.81M |
| March 31, 2019 | 0.405M |
| December 31, 2018 | 0.433M |
| September 30, 2018 | 0.233M |
| June 30, 2018 | 0.072M |
| March 31, 2018 | 0.087M |
| December 31, 2017 | 0.089M |
| September 30, 2017 | 0.063M |
| June 30, 2017 | 0.101M |
| March 31, 2017 | 0.16M |
| December 31, 2016 | 0.601M |
| September 30, 2016 | 0.016M |
| June 30, 2016 | 0.076M |
| March 31, 2016 | 0.046M |
| December 31, 2015 | 0.033M |
| September 30, 2015 | 0.093M |
| June 30, 2015 | 0.025M |
| March 31, 2015 | 0.181M |
| December 31, 2014 | 0.0708M |
| September 30, 2014 | 0.0701M |
| June 30, 2014 | 0.0356M |
| March 31, 2014 | 0.0602M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viatris, Inc. | 245.20M |
| Zevra Therapeutics, Inc. | 4.486M |
| Indivior Pharmaceuticals, Inc. | 7.00M |
| Liquidia Corp. | 16.88M |
| 60 Degrees Pharmaceuticals, Inc. | 0.5987M |